"
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market
Analysis to 2024 "is
the latest addition to MRR.Biz industry research reports collection.
Bipolar
disorder is a mental disorder characterized by periods of mania and
depression. The frequency, severity, and pattern of these episodes
can vary considerably over time and between individuals, making
bipolar disorder one of the most challenging psychiatric disorders to
manage. The Bipolar
Disorder Market
is widely genericized, with additional key brands expected to face
patent or data exclusivity expiries during the forecast period. The
bipolar disorder market size is anticipated to contract significantly
between 2014 and 2024, driven largely by the generic erosion of
Otsukas Abilify, the highest selling bipolar disorder product in
2014. The uptake of novel atypical antipsychotic products will be a
principal driver of growth over the forecast period, as these
products offer clinical advantages that will drive strong uptake.
However, sales of these agents will be limited by the continued
utilization of established generic products. There are currently only
two products in Phase III development, which indicates that bipolar
disorder will remain a field of high unmet need during the forecast
period.
Download Sample copy of this
Report at :
http://www.marketresearchreports.biz/sample/sample/725328
Highlights
Key Questions Answered
-
The bipolar disorder market is heavily genericized and many key
players have chosen to deprioritize the indication. In light of this,
what are the current clinical and environmental unmet needs? Will
there be opportunities in this market for drug developers throughout
the forecast period?
-
The current late-stage bipolar disorder pipeline is sparse, with only
two products in Phase III development. What impact will these drugs
have on the market? How will they affect the treatment algorithm for
bipolar disorder? Will these drugs fulfil any of the unmet needs for
bipolar disorder?
-
The management of bipolar disorder patients is challenging and a
large number of variables can impact treatment outcomes. How does the
diagnosis and treatment of bipolar disorder differ amongst the 8MM?
Which treatment options are most commonly prescribed in each market,
and how will prescribing patterns change over the forecast period?
Key Findings
-
The main driver of growth in the bipolar disorder market will be the
uptake of novel atypical antipsychotic products, such as
Otsuka/Lundbecks Abilify Maintena and Allergan/Gedeon
Richter/Mitsubishi Tanabes Vraylar. These agents are forecast to be
the highest selling bipolar disorder products by 2024, accounting for
34.9% of the bipolar disorder market in the 8MM.
-
There are very few products approved for the treatment of major
depressive episodes, despite the fact that patients most commonly
experience this episode type. This unmet need is not expected to be
addressed during the forecast period due to the sparsity of the
late-stage pipeline.
-
The biggest barrier for growth in the bipolar disorder market will be
fierce competition from generic products. This limits market
opportunities for new and existing players, as uptake of novel
pipeline products would be hindered by their premium price point.
-
Considerable opportunity remains for products with superior safety
profiles compared to the currently available drugs. KOLs noted that
EPS and metabolic changes were significant concerns related to the
antipsychotic drugs.
Browse
Press Releases by Prweb :
Scope
- Overview of bipolar disorder,
including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and treatment guidelines.
- Annualized bipolar disorder
market revenue, annual cost of therapy and treatment usage pattern
data from 2014 and forecast for ten years to 2024.
- Key topics covered include
market characterization, unmet needs, R&D and clinical trials
assessment, late stage clinical trial analysis and implications for
the bipolar disorder therapeutics market.
- Pipeline analysis: focus on
two late-stage pipeline bipolar disorder drugs, discussing emerging
trends as well as an overview of earlier phase drugs and a top-line
analysis of off-label treatments.
- Analysis of the current and
future market competition in the global bipolar disorder therapeutics
market. Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you
to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global bipolar
disorder therapeutics market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global bipolar
disorder therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global bipolar disorder therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment